1-3 of 3
Amal El-Beshlawy
Close
Sort by
Journal Articles

Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort

Shermarke Hassan, Guido Baselli, Luca Mollica, Riccardo L. Rossi, Himani Chand, Amal El-Beshlawy, Mohsen Elalfy, Vijay Ramanan, Peyman Eshghi, Mehran Karimi, Roberta Palla, Frits R. Rosendaal, Flora Peyvandi
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2880–2889.
https://doi.org/10.1182/bloodadvances.2023011388
Published: 2024
Includes: Supplemental data
Journal Articles

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years

Clinical Trials & Observations
Mohsen S. Elalfy, Mona Hamdy, Amal El-Beshlawy, Fatma S. E. Ebeid, Mohamed Badr, Julie Kanter, Baba Inusa, Amira A. M. Adly, Suzan Williams, Yurdanur Kilinc, David Lee, Caroline Fradette, Anna Rozova, Noemi Toiber Temin, Fernando Tricta, Janet L. Kwiatkowski
Journal: Blood Advances
Blood Adv (2023) 7 (4): 611–619.
https://doi.org/10.1182/bloodadvances.2021006778
Published: 2023
Includes: Supplemental data
Journal Articles

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study

Clinical Trials & Observations
Janet L. Kwiatkowski, Mona Hamdy, Amal El-Beshlawy, Fatma S. E. Ebeid, Mohammed Badr, Abdulrahman Alshehri, Julie Kanter, Baba Inusa, Amira A. M. Adly, Suzan Williams, Yurdanur Kilinc, David Lee, Fernando Tricta, Mohsen S. Elalfy
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1243–1254.
https://doi.org/10.1182/bloodadvances.2021004938
Published: 2022
Includes: Supplemental data